09/21/2026 | Dr. Adriana Scheliga | Medscape

https://portugues.medscape.com/viewarticle/sinergia-entre-ci%C3%AAncia-e-ind%C3%BAstria-2026a1000z2k?form=fpf 

The incorporation of new technologies into medicine does not happen through spontaneous generation, nor does it occur in isolation. Behind every innovative molecule, every redirected cell therapy, or every precision protocol endorsed at major congresses lies a complex, interconnected ecosystem comprising leading universities, translational research centers, high-complexity hospitals, the pharmaceutical industry, biotechnology companies, and advanced medical training programs.

Contemporary scientific literature demonstrates that so-called "elite" medical education—when deeply connected to applied research and structured collaboration with industry—acts as the primary catalyst for the development and safe adoption of healthcare innovations.

This contemporary pedagogical model not only trains physicians with greater technical depth but also drastically shortens the gap between bench discovery and bedside application. In onco-hematology—where tumor biology dictates prognosis and every therapeutic advance represents a tangible survival gain—this agility ceases to be merely a distinguishing factor and becomes an ethical imperative.

Contemporary training: from passive knowledge to innovation leadership
Historically, medical education centered on the passive absorption of established guidelines and the repetition of traditional clinical practice. Today, leading global healthcare institutions and medical schools are profoundly expanding this model, integrating competencies in information technology, artificial intelligence, health regulation, and complex systems management into the medical curriculum. International bibliometric analyses reveal a marked acceleration in the creation of health innovation and entrepreneurship programs within academic settings. Curricula at centers of excellence now incorporate courses dedicated to medical device development, intellectual property, regulatory processes, and leadership within healthcare ecosystems.

This represents a fundamental paradigm shift: the market and society no longer demand only physicians who know how to use new technologies, but also professionals capable of participating in the design, testing, and validation of these tools alongside multidisciplinary teams.

Incubators and applied science
In countries where medical education and research set the standard, true synergy between academia and the industrial sector is realized through the creation of innovation hubs directly linked to hospital complexes. When students, residents, and researchers interact daily with engineers, data scientists, biotech startups, and regulatory affairs specialists, the capacity to solve clinical problems increases exponentially.

Immersive medical innovation experiences—such as the extended hackathons hosted by universities like Stanford—demonstrate that practical, interdisciplinary engagement accelerates the translation of scientific concepts into applicable products and therapies. Furthermore, immersion programs and internships at MedTech accelerators enhance a professional's scientific maturity, enabling physicians to act as a solid, reliable bridge between real patient needs and technological development.

Teaching methodology itself reflects this transformation. The incorporation of advanced clinical simulations, big data analysis, and training in high-fidelity virtual environments allows for the consolidation of complex knowledge and enables medical practice to adapt much more rapidly to new therapeutic realities.

High-performance education and its impact on clinical outcomes
There is a direct correlation between the depth of medical education and improvements in health indicators. The concept of "powerful medical education"—grounded in the science of expertise, deliberate practice, and recurring simulation training—demonstrates an unequivocal real-world impact.

Clinical and healthcare management studies confirm that professionals undergoing this level of educational rigor exhibit lower procedural complication rates, greater efficiency in the use of high-cost technological resources, improved patient communication, and more consistent therapeutic outcomes. There is a clear return in terms of both the quality of life provided and the sustainability of the healthcare system.

Large-scale institutional initiatives—such as the *Accelerating Change in Medical Education* consortium led by the American Medical Association (AMA)—demonstrate that such curricular reforms need not remain confined to isolated pockets of excellence. When clearly structured and funded, they reshape the medical culture across an entire network, directly benefiting thousands of patients.

The role of industry and medical governance in onco-hematology
The pharmaceutical and biotechnology industries are the driving force behind the development of new molecules; however, innovation only fulfills its social purpose when rigorously and safely translated into the daily practice of clinics and infusion centers.

In this context, ethical and transparent collaboration among researchers, the medical community, and healthcare companies is essential. Medical Affairs professionals, for instance, play an indispensable technical role in interpreting Phase 3 clinical trial data, organizing continuing medical education programs, and ensuring the appropriate use of complex medications. Similarly, technical support and training provided by companies—whether for implementing devices or managing infusion platforms—ensure that the care team’s learning curve is navigated with maximum patient safety.

Few fields demonstrate the urgency of this synergy as clearly as onco-hematology. Molecularly targeted therapies, monoclonal and bispecific antibodies, and CAR-T cell engineering are the direct results of decades of technical cooperation between academic research laboratories and the pharmaceutical industry. The more skilled and up-to-date the specialist, the greater their critical capacity to select the appropriate strategy, precisely manage adverse events, and offer the patient the best chance of a positive response.

The notion that pure science and the industrial sector should operate in parallel, disconnected universes no longer holds weight in contemporary hematology. Sustainable medical progress stems precisely from the balance between scientific rigor, technological innovation, excellent continuing education, and absolute ethical transparency in professional relationships. It is from this convergence that treatments emerge which are currently rewriting patients' stories.

In the Brazilian landscape—where access to healthcare innovation still faces deep structural bottlenecks and a stark disparity between public and private systems—this integration takes on even greater urgency. Strengthening clinical research hubs within our academic centers and centers of excellence, encouraging the country's participation in global Phase 3 trials, and fostering ethical partnerships with the industry are the most effective ways to ensure that cutting-edge technologies actually reach the population.

For the field of onco-hematology in Brazil, investing in advanced medical education and scientific governance is not merely a strategy for professional development; it is the indispensable engine for democratizing precision medicine and translating response times into real life for patients in the country.

How do you view the role of clinical research and industry partnerships in accelerating access to innovation in Brazil?

Share your perspective in the comments, and let’s delve deeper into this discussion!

Dr. Adriana Scheliga is a hematologist and clinical oncologist, a researcher specializing in CLL, lymphomas, and multiple myeloma, and a member of the ABHH Advisory Board as well as the institution's Non-Hodgkin Lymphoma and CLL committees.